Acidic Environment-Responsive Metal Organic Framework-Mediated Dihydroartemisinin Delivery for Triggering Production of Reactive Oxygen Species in Drug-Resistant Lung Cancer
Xiaojie Yan,Xueying Zhao,Mingde Fan,Wenfu Zheng,Guanxiong Zhu,Bin Li,Le Wang
DOI: https://doi.org/10.2147/ijn.s451042
IF: 7.033
2024-04-30
International Journal of Nanomedicine
Abstract:Xiaojie Yan, 1, &ast Xueying Zhao, 2, &ast Mingde Fan, 3 Wenfu Zheng, 4, 5 Guanxiong Zhu, 6 Bin Li, 1 Le Wang 1 1 Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China; 2 Department of Transfusion, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 3 Department of Neurosurgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 4 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for NanoScience and Technology, Beijing, People's Republic of China; 5 School of Nanoscience and Engineering, University of Chinese Academy of Sciences, Beijing, People's Republic of China; 6 Department of Preventive Dentistry, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Le Wang; Bin Li, Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China, Tel/Fax +86-791-86362367, Email ; Background: Dihydroartemisinin (DHA) has emerged as a promising candidate for anticancer therapy. However, the application of DHA in clinics has been hampered by several limitations including poor bioavailability, short circulation life, and low solubility, significantly restricting its therapeutic efficacy and leading to notable side effects during the treatment. Purpose: We present DHA-loaded zeolitic imidazolate framework-8 (D-ZIF) with controllable and targeted DHA release properties, leading to enhanced antitumor effects while reducing potential side effects. Methods: D-ZIF was prepared by one-pot synthesis method using methylimidazole (MIM), Zn(NO 3 ) 2 • 6H 2 O and DHA. We characterized the physical and chemical properties of D-ZIF by TEM, DLS, XRD, FT-IR, and TG. We measured the drug loading efficiency and the cumulative release of DHA in different pH conditions. We evaluated the cytotoxicity of D-ZIF on renal cell carcinoma (RCC786-O), glioma cells (U251), TAX-resistant human lung adenocarcinoma (A549-TAX) cells by CCK8 in vitro. We explored the possible antitumor mechanism of D-ZIF by Western blot. We evaluated the biocompatibility and hemolysis of D-ZIF and explored the in vivo antitumor efficiency in mice model by TUNEL testing and blood biomarker evaluations. Results: D-ZIF showed rhombic dodecahedral morphology with size of 129± 7.2 nm and possessed a noticeable DHA encapsulation efficiency (72.9%). After 48 hours, D-ZIF released a cumulative 70.0% of the loaded DHA at pH 6.5, and only 42.1% at pH 7.4. The pH-triggered programmed release behavior of D-ZIF could enhance anticancer effect of DHA while minimizing side effects under normal physiological conditions. Compared with the free DHA group with 31.75% of A549-TAX cell apoptosis, the percentage of apoptotic cells was approximately 76.67% in the D-ZIF group. D-ZIF inhibited tumor growth by inducing tumor cell apoptosis through the mechanism of ROS production and regulation of Nrf2/HO-1 and P38 MAPK signaling pathways. D-ZIF showed potent effects in treating tumors with high safety in vivo. Conclusion: This pH-responsive release mechanism enhanced the targeting efficiency of DHA towards tumor cells, thereby increasing drug concentration in tumor sites with negligible side effects. Herein, D-ZIF holds great promise for curing cancers with minimal adverse effects. Keywords: MOF, drug delivery, controlled release, cancer therapy Cancers especially lung cancer pose a significant threat to human health. 1–3 For a considerable duration, patients facing cancers had limited options for treatment, primarily relying on surgery, radiation therapy, and chemotherapy, either individually or in combination. 4 A significant challenge associated with chemotherapy is the development of drug resistance. 5 Multi-drug resistance (MDR) in cancer cells, whether intrinsic or acquired, leads to reduced drug absorption and increased drug efflux, representing a substantial obstacle to the therapeutic effectiveness of drugs. In tackling these challenges, nanotechnology-based delivery systems have demonstrated the ability to provide controlled and targeted delivery, 6 thereby enhancing the intracellular availability of drugs and exploring opportunities to overcome MDR. 7 Recently, the active derivatives of traditional Chinese medicine have emerged as c -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology